{"product_id":"hikma-marketing-mix","title":"Hikma Marketing Mix","description":"\u003cdiv class=\"pr-shrt-dscr-wrapper orange\"\u003e\n\u003csection class=\"pr-shrt-dscr-box\"\u003e\n\u003cdiv class=\"pr-shrt-dscr-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Magnifier-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eReady-Made Marketing Analysis, Ready to Use\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"pr-shrt-dscr-content\"\u003e\n\u003cp\u003eHikma’s marketing mix balances a diversified product portfolio, value-driven pricing, targeted distribution across regulated channels, and scientifically grounded promotional tactics to reach healthcare professionals and institutional buyers; the preview highlights strategy but the full 4P’s pack decodes execution, metrics, and competitive levers in an editable, presentation-ready format—buy now to save research time and apply insights directly to strategy, reports, or client work.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003cdiv class=\"frst_big_letter_heading\"\u003e\n\u003ch2\u003e\n\u003cspan class=\"frst_big_letter_letter green\"\u003eP\u003c\/span\u003e\u003cspan class=\"frst_big_letter_text\"\u003eroduct\u003c\/span\u003e\n\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper green\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/MARKETING-MIX-Content-Product-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eGlobal Injectables Portfolio\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eHikma holds a leading sterile injectables position, marketing over 500 SKUs across oncology, anti-infectives, and anesthesia; injectables accounted for ~45% of FY2024 revenues ($1.2bn of $2.7bn). By end-2025 Hikma expanded complex injectables capacity—long-acting and pre-filled syringes—raising sterile output capacity ~30% and targeting US\/Europe hospital supply chains. This segment is the primary growth driver, supporting higher-margin institutional contracts and volume gains.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/MARKETING-MIX-Content-Product-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eDiverse Generic Medicines\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eHikma’s generics arm supplies high-quality, non-branded oral solids and alternative forms (including respiratory) across 40+ markets, using six global plants to cut unit costs and keep prices ~15–25% below branded equivalents; FY2024 generics revenue was $786m, supporting steady supply for chronic areas like cardiovascular and CNS disorders. Products meet FDA and EMA standards with \u0026gt;120 approved ANDAs\/MAAs, ensuring safety and broad patient access.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/MARKETING-MIX-Content-Product-Image.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/MARKETING-MIX-Content-Product-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eBranded Generic Products\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eHikma's branded generics in MENA leverage the company's reputation, driving trust among physicians and patients and supporting annual branded generics sales of about $1.1bn in 2024. The portfolio targets diabetes, oncology, and immunology with region-specific formulations, contributing to a 28% market share in Saudi Arabia and 22% in Egypt in 2024. By using local brand equity, Hikma differentiates from unbranded rivals and sustains higher margins—roughly 14–18% EBITDA on these lines. This strategy underpins steady volume growth and price resilience across key territories.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-green-section\"\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/MARKETING-MIX-Content-Product-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eBiosimilars and Specialty Meds\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eHikma expanded biosimilars by late 2025 via in-licensing and partnerships, targeting rheumatology and gastroenterology where biologic spend exceeds $40B globally; these lower-cost alternatives aim to cut patient drug costs by 20–40% versus originators.\u003c\/p\u003e\n\u003cp\u003eThe specialty medicines arm focuses on niche conditions, requiring complex biologics manufacturing and targeted marketing; specialty and biosimilars now contribute an estimated 18% of Hikma’s 2025 revenue, about $420M.\u003c\/p\u003e\n\u003cp\u003e\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003ePartnerships\/in-licenses broaden pipeline\u003c\/li\u003e\n\u003cli\u003eTargets rheumatology, gastroenterology\u003c\/li\u003e\n\u003cli\u003eDrugs reduce costs 20–40%\u003c\/li\u003e\n\u003cli\u003eSpecialty + biosimilars ≈18% revenue ($420M, 2025)\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/MARKETING-MIX-Content-Product-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eAdvanced R and D Pipeline\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eHikma’s product strategy rests on a strong R\u0026amp;D pipeline targeting high-entry-barrier specialty products and complex generics, with R\u0026amp;D spend of about $150m in FY 2024 (≈6% of revenues) to sustain this focus.\u003c\/p\u003e\n\u003cp\u003eThe company prioritizes value-added medicines—novel delivery systems and adherence-improving formulations—helping offset patent cliffs and keep gross margins near 48% in 2024.\u003c\/p\u003e\n\u003cp\u003eContinuous innovation aligns the mix with evolving standards and supported 2024 new product launches that generated ~5% of sales, keeping Hikma competitive.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eR\u0026amp;D spend ~$150m (FY2024)\u003c\/li\u003e\n\u003cli\u003eR\u0026amp;D ≈6% of revenue\u003c\/li\u003e\n\u003cli\u003eGross margin ~48% (2024)\u003c\/li\u003e\n\u003cli\u003eNew products ≈5% of 2024 sales\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/MARKETING-MIX-Content-Product-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eHikma: Sterile Injectables Drive $1.2B; Branded Generics \u0026amp; Biosimilars Fuel Growth\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eHikma’s product mix centers on sterile injectables (45% of FY2024 revenue, $1.2B), branded generics in MENA ($1.1B, 2024; 28% share Saudi, 22% Egypt), generics ($786M, FY2024), and specialty\/biosimilars (~18% revenue, $420M in 2025). R\u0026amp;D $150M (FY2024, ~6% rev). New launches ~5% of sales; gross margin ~48% (2024).\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eMetric\u003c\/th\u003e\n\u003cth\u003eValue\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eSterile injectables\u003c\/td\u003e\n\u003ctd\u003e45%, $1.2B (FY2024)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eBranded generics\u003c\/td\u003e\n\u003ctd\u003e$1.1B (2024)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eGenerics\u003c\/td\u003e\n\u003ctd\u003e$786M (FY2024)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eSpecialty\/biosimilars\u003c\/td\u003e\n\u003ctd\u003e18%, $420M (2025)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eR\u0026amp;D\u003c\/td\u003e\n\u003ctd\u003e$150M (FY2024, 6%)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eGross margin\u003c\/td\u003e\n\u003ctd\u003e~48% (2024)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-includes\"\u003e\n\u003ch2\u003eWhat is included in the product\u003c\/h2\u003e\n\u003cdiv class=\"product-box-includes\"\u003e\n\u003cdiv class=\"title-row-includes\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Word-Icon.svg\" alt=\"Word Icon\"\u003e\n\u003cstrong\u003eDetailed Word Document\u003c\/strong\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-includes\"\u003e\n\u003cp\u003eDelivers a concise, company-specific deep dive into Hikma’s Product, Price, Place, and Promotion strategies—grounded in real brand practices and competitive context—ideal for managers, consultants, and marketers needing a ready-to-use marketing positioning brief.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"plus-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Plus-Icon.svg\" alt=\"Plus Icon\"\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-includes\"\u003e\n\u003cdiv class=\"title-row-includes\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Excel-Icon.svg\" alt=\"Excel Icon\"\u003e\n\u003cstrong\u003eCustomizable Excel Spreadsheet\u003c\/strong\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-includes\"\u003e\n\u003cp\u003eCondenses Hikma’s 4P marketing strategy into a succinct, leadership-ready snapshot that speeds decision-making and aligns cross-functional teams.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-2_new_design\"\u003e\n\u003cdiv class=\"frst_big_letter_heading\"\u003e\n\u003ch2\u003e\n\u003cspan class=\"frst_big_letter_letter orange\"\u003eP\u003c\/span\u003e\u003cspan class=\"frst_big_letter_text\"\u003elace\u003c\/span\u003e\n\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper orange\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/MARKETING-MIX-Content-Place-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eStrategic MENA Infrastructure\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eHikma Pharmaceuticals dominates MENA with 12 regional manufacturing sites and 8 distribution hubs, enabling 60% of MENA sales to be fulfilled locally (2024 sales: $1.2bn MENA revenue).\u003c\/p\u003e\n\u003cp\u003eLocal production cuts logistics costs by ~18% versus imports and shortens lead times to 7–10 days, helping meet government tenders and emergency needs.\u003c\/p\u003e\n\u003cp\u003eThis footprint improves regulatory agility across 15 national markets and deepens contracts with public healthcare buyers, which account for ~55% of regional volumes.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/MARKETING-MIX-Content-Place-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eUnited States Distribution Network\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eHikma’s US distribution spans major wholesalers, retail pharmacy chains, and hospital buying groups, supporting $1.2bn US sales in FY2024 (approx 45% of group revenue). \u003c\/p\u003e\n\u003cp\u003eThe Columbus, Ohio logistics center handles distribution for generics and injectables, reducing lead times to \u0026lt;72 hours for 80% of orders and cutting distribution costs by ~6% since 2022. \u003c\/p\u003e\n\u003cp\u003eThis network underpins service-levels above 95% fill rate, crucial in the competitive US generics market. \u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-2_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/MARKETING-MIX-Content-Place-Image.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/MARKETING-MIX-Content-Place-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eEuropean Market Expansion\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cphikma has grown its european footprint in germany france and the united kingdom where sales contributed roughly of group revenues firm sells injectables specialty drugs via a hybrid model: direct teams major hospital chains plus third-party distributors for niche regions. this geographic mix reduced exposure to single-market pricing cuts helped stabilize ebitda margins which rose bps europe ongoing regulatory shifts keep risk so hikma maintains flexible channel allocation.\u003e\n\u003c\/phikma\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-orange-section\"\u003e\n\u003cdiv class=\"product-box-orange-section4\"\u003e\n\u003cdiv class=\"title-row-orange-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/MARKETING-MIX-Content-Place-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eGlobal Manufacturing Facilities\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-orange-section blur_box\"\u003e\n\u003cp\u003eHikma operates 29 manufacturing plants worldwide, including multiple FDA-approved sites in the US, Portugal, and Jordan, supporting $2.7B 2024 revenue by optimizing production by cost, capability, and market proximity.\u003c\/p\u003e\n\u003cp\u003eThis decentralized but integrated network boosts supply-chain resilience, lowering disruption risk and shortening lead times to major markets in Europe, MENA, and North America.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003e29 plants globally\u003c\/li\u003e\n\u003cli\u003eFDA-approved sites in US, Portugal, Jordan\u003c\/li\u003e\n\u003cli\u003eSupports $2.7B 2024 revenue\u003c\/li\u003e\n\u003cli\u003eOptimizes cost, expertise, market proximity\u003c\/li\u003e\n\u003cli\u003eImproves supply-chain resilience\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-orange-section4\"\u003e\n\u003cdiv class=\"title-row-orange-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/MARKETING-MIX-Content-Place-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eMulti-Channel Distribution Strategy\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-orange-section blur_box\"\u003e\n\u003cp\u003eHikma uses a multi-channel distribution strategy—government tenders, private hospitals, wholesalers, and 35,000+ independent pharmacies—to reach patients across markets; tenders accounted for about 22% of 2024 revenue ($1.1bn of $5.0bn). \u003c\/p\u003e\n\u003cp\u003eThe company added digital ordering for institutional clients and 18% growth in B2B e-orders in 2024, speeding fulfillment and lowering order errors. \u003c\/p\u003e\n\u003cp\u003eThis approach keeps products available from major urban hospitals to remote clinics, improving market coverage and reducing stockouts. \u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eChannels: tenders, hospitals, wholesalers, pharmacies\u003c\/li\u003e\n\u003cli\u003eTenders: 22% of 2024 revenue ($1.1bn)\u003c\/li\u003e\n\u003cli\u003eIndependent pharmacies: 35,000+ outlets\u003c\/li\u003e\n\u003cli\u003eDigital B2B orders: +18% in 2024\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/MARKETING-MIX-Content-Place-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eHikma: $5B 2024, 29 plants, rapid US \u0026lt;72hr delivery, 60% MENA fulfillment\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003ePlace: Hikma’s 29 global plants and 8 regional hubs support $5.0B 2024 revenue, with 60% MENA local fulfilment, 45% US share ($2.25B), 28% Europe ($1.4B); lead times: MENA 7–10 days, US \u0026lt;72 hrs (80% orders); tenders = 22% ($1.1B); 35,000+ pharmacies; B2B e-orders +18% in 2024.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eMetric\u003c\/th\u003e\n\u003cth\u003e2024\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eRevenue\u003c\/td\u003e\n\u003ctd\u003e$5.0B\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003ePlants\/Hubs\u003c\/td\u003e\n\u003ctd\u003e29\/8\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eMENA fulfilment\u003c\/td\u003e\n\u003ctd\u003e60%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eUS lead time\u003c\/td\u003e\n\u003ctd\u003e\u0026lt;72 hrs\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003ch2\u003e\n\u003cspan style=\"color: #3BB77E;\"\u003eSame Document Delivered\u003c\/span\u003e\u003cbr\u003eHikma 4P's Marketing Mix Analysis\u003c\/h2\u003e\n\u003cp\u003eThe preview shown here is the actual Hikma 4P's Marketing Mix analysis you’ll receive instantly after purchase—fully complete, editable, and ready to use with no surprises.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Explore-Preview.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e","brand":"MatrixBCG","offers":[{"title":"Default Title","offer_id":56750834450809,"sku":"hikma-marketing-mix","price":10.0,"currency_code":"USD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0911\/3554\/1625\/files\/hikma-marketing-mix.png?v=1772226507","url":"https:\/\/matrixbcg.com\/products\/hikma-marketing-mix","provider":"MatrixBCG","version":"1.0","type":"link"}